Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984087551> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W1984087551 endingPage "55" @default.
- W1984087551 startingPage "55" @default.
- W1984087551 abstract "Molecular resistance mechanisms affecting the efficiency of receptor tyrosine kinase inhibitors such as gefitinib in non-small-cell lung cancer (NSCLC) cells are not fully understood. Amphiregulin (Areg) overexpression has been proposed to predict NSCLC resistance to gefitinib and we have established that Areg-overexpressing H358 NSCLC cells resist apoptosis. Here, we demonstrate that Areg prevents gefitinib-induced apoptosis in NSCLC cells. We show that H358 cells are resistant to gefitinib in contrast to H322 cells, which do not overexpress Areg. Inhibition of Areg expression by small-interfering RNAs (siRNAs) restores gefitinib sensitivity in H358 cells, whereas addition of recombinant Areg confers resistance in H322 cells. Areg knockdown overcomes resistance to gefitinib and induced apoptosis in NSCLC H358 cells in vitro and in vivo. Under gefitinib treatment, Areg decreases the expression of the proapoptotic protein BAX, inhibits its conformational change and its mitochondrial translocation. Thus, in the presence of Areg, gefitinib-mediated apoptosis is reduced because BAX is sequestered in the cytoplasm. This suggests that treatments using epidermal growth factor receptor (EGFR) inhibitors may be poorly efficient in patients with elevated levels of Areg. These findings indicate the need for inhibition of Areg to enhance the efficiency of the EGFR inhibitors in patients suffering NSCLC." @default.
- W1984087551 created "2016-06-24" @default.
- W1984087551 creator A5008227857 @default.
- W1984087551 creator A5019781329 @default.
- W1984087551 creator A5021601963 @default.
- W1984087551 creator A5023172789 @default.
- W1984087551 creator A5028222428 @default.
- W1984087551 creator A5052890942 @default.
- W1984087551 creator A5053031492 @default.
- W1984087551 creator A5080479183 @default.
- W1984087551 date "2010-06-01" @default.
- W1984087551 modified "2023-09-26" @default.
- W1984087551 title "212 The a5β1 integrin is a therapeutic target for human glioblastoma and participates to chemoresistance" @default.
- W1984087551 doi "https://doi.org/10.1016/s1359-6349(10)71019-3" @default.
- W1984087551 hasPublicationYear "2010" @default.
- W1984087551 type Work @default.
- W1984087551 sameAs 1984087551 @default.
- W1984087551 citedByCount "0" @default.
- W1984087551 crossrefType "journal-article" @default.
- W1984087551 hasAuthorship W1984087551A5008227857 @default.
- W1984087551 hasAuthorship W1984087551A5019781329 @default.
- W1984087551 hasAuthorship W1984087551A5021601963 @default.
- W1984087551 hasAuthorship W1984087551A5023172789 @default.
- W1984087551 hasAuthorship W1984087551A5028222428 @default.
- W1984087551 hasAuthorship W1984087551A5052890942 @default.
- W1984087551 hasAuthorship W1984087551A5053031492 @default.
- W1984087551 hasAuthorship W1984087551A5080479183 @default.
- W1984087551 hasConcept C170493617 @default.
- W1984087551 hasConcept C173396325 @default.
- W1984087551 hasConcept C185592680 @default.
- W1984087551 hasConcept C190283241 @default.
- W1984087551 hasConcept C22615655 @default.
- W1984087551 hasConcept C2779438470 @default.
- W1984087551 hasConcept C2780580887 @default.
- W1984087551 hasConcept C2780806702 @default.
- W1984087551 hasConcept C502942594 @default.
- W1984087551 hasConcept C54009773 @default.
- W1984087551 hasConcept C54355233 @default.
- W1984087551 hasConcept C55493867 @default.
- W1984087551 hasConcept C81885089 @default.
- W1984087551 hasConcept C86803240 @default.
- W1984087551 hasConceptScore W1984087551C170493617 @default.
- W1984087551 hasConceptScore W1984087551C173396325 @default.
- W1984087551 hasConceptScore W1984087551C185592680 @default.
- W1984087551 hasConceptScore W1984087551C190283241 @default.
- W1984087551 hasConceptScore W1984087551C22615655 @default.
- W1984087551 hasConceptScore W1984087551C2779438470 @default.
- W1984087551 hasConceptScore W1984087551C2780580887 @default.
- W1984087551 hasConceptScore W1984087551C2780806702 @default.
- W1984087551 hasConceptScore W1984087551C502942594 @default.
- W1984087551 hasConceptScore W1984087551C54009773 @default.
- W1984087551 hasConceptScore W1984087551C54355233 @default.
- W1984087551 hasConceptScore W1984087551C55493867 @default.
- W1984087551 hasConceptScore W1984087551C81885089 @default.
- W1984087551 hasConceptScore W1984087551C86803240 @default.
- W1984087551 hasIssue "5" @default.
- W1984087551 hasLocation W19840875511 @default.
- W1984087551 hasOpenAccess W1984087551 @default.
- W1984087551 hasPrimaryLocation W19840875511 @default.
- W1984087551 hasRelatedWork W1983803621 @default.
- W1984087551 hasRelatedWork W2006881103 @default.
- W1984087551 hasRelatedWork W2018360198 @default.
- W1984087551 hasRelatedWork W2168734527 @default.
- W1984087551 hasRelatedWork W2367047681 @default.
- W1984087551 hasRelatedWork W2796860503 @default.
- W1984087551 hasRelatedWork W2924811393 @default.
- W1984087551 hasRelatedWork W4252253415 @default.
- W1984087551 hasRelatedWork W4361948002 @default.
- W1984087551 hasRelatedWork W4361953992 @default.
- W1984087551 hasVolume "8" @default.
- W1984087551 isParatext "false" @default.
- W1984087551 isRetracted "false" @default.
- W1984087551 magId "1984087551" @default.
- W1984087551 workType "article" @default.